Skip to main content
Premium Trial:

Request an Annual Quote

If a Tree Falls in the Woods …

Ivan Oransky at Retraction Watch asks: "If a paper appears online but then is withdrawn ... before it is 'officially' published, did anyone hear it fall?" Because publishers' policies vary, he says, there's no clear consensus as to whether "something that is freely available online is published," which, consequently, "has ramifications for whether you can retract a paper like that." In discussing two scenarios in which papers that appeared online were withdrawn, Oranksy calls for increased transparency on the part of the publishers. "So if you end up at an abstract and all you see is 'Withdrawn' ... you might raise your eyebrows a bit and wonder what happened," he says. "It shouldn't take a call or e-mail to the journal or authors to find out." To that end, journal editors ought to make their rationales for withdrawals public, Oransky suggests.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.